BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 29380207)

  • 1. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
    Jansson S; Aaltonen K; Bendahl PO; Falck AK; Karlsson M; Pietras K; Rydén L
    Breast Cancer Res Treat; 2018 Jun; 169(2):231-241. PubMed ID: 29380207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    Forte L; Turdo F; Ghirelli C; Aiello P; Casalini P; Iorio MV; D'Ippolito E; Gasparini P; Agresti R; Belmonte B; Sozzi G; Sfondrini L; Tagliabue E; Campiglio M; Bianchi F
    BMC Cancer; 2018 May; 18(1):586. PubMed ID: 29792166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
    Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
    PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.
    Ehnman M; Missiaglia E; Folestad E; Selfe J; Strell C; Thway K; Brodin B; Pietras K; Shipley J; Östman A; Eriksson U
    Cancer Res; 2013 Apr; 73(7):2139-49. PubMed ID: 23338608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
    Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
    Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer.
    Park SY; Kim HM; Koo JS
    Breast Cancer Res Treat; 2015 Feb; 149(3):727-41. PubMed ID: 25667103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.
    Wehler TC; Frerichs K; Graf C; Drescher D; Schimanski K; Biesterfeld S; Berger MR; Kanzler S; Junginger T; Galle PR; Moehler M; Gockel I; Schimanski CC
    Oncol Rep; 2008 Mar; 19(3):697-704. PubMed ID: 18288404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
    Carvalho I; Milanezi F; Martins A; Reis RM; Schmitt F
    Breast Cancer Res; 2005; 7(5):R788-95. PubMed ID: 16168125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitriol inhibits growth response to Platelet-Derived Growth Factor-BB in human prostate cells.
    Nazarova N; Golovko O; Bläuer M; Tuohimaa P
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):189-96. PubMed ID: 15862965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and clinical significance of PDGFRalpha and PDGFRbeta in colorectal cancer].
    Zhu HT; Han J; Ma L
    Ai Zheng; 2008 Jun; 27(6):654-60. PubMed ID: 18570744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.
    Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
    Eur J Pharmacol; 2021 Mar; 895():173868. PubMed ID: 33460613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine activation of platelet-derived growth factor receptor α in metastatic papillary thyroid cancer.
    Adewuyi EE; Deschenes J; Lopez-Campistrous A; Kattar MM; Ghosh S; McMullen TPW
    Hum Pathol; 2018 May; 75():146-153. PubMed ID: 29408504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor alpha in primary central nervous system lymphoma.
    Karabatsou K; Pal P; Dodd S; Mat A; Haylock B; Aguirreburualde M; Moxam N; Pinson-Ellis W; Broome J; Rainov NG
    J Neurooncol; 2006 Sep; 79(2):171-9. PubMed ID: 16850112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
    ; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
    Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer.
    Reinmuth N; Liersch R; Raedel M; Fehrmann F; Fehrmann N; Bayer M; Schwoeppe C; Kessler T; Berdel W; Thomas M; Mesters RM
    Int J Cancer; 2009 Apr; 124(7):1535-44. PubMed ID: 19115205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor status is highly conserved during tumor progression of breast cancer.
    Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
    BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
    Xu L; Tong R; Cochran DM; Jain RK
    Cancer Res; 2005 Jul; 65(13):5711-9. PubMed ID: 15994946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.